RESEARCH TRIANGLE PARK - RedHill Biopharma is reporting a 62% reduction in mortality for severe COVID-19 patients using its investigational oral pill-based
RedHill Biopharma erhält Notice of Allowance zur Einreichung der Patentanmeldungen für Opganib und RHB-107 zur Behandlung von COVID-19 in den USA finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
TEL AVIV, Israel and RALEIGH, NC, May 26, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib
[1] and RHB-107 (upamostat)
[2] as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus.
Both opaganib and RHB-107 are novel COVID-19 therapeutic candidates, in oral pill form, with dual mechanism of action effects. Both are host-targeted and are therefore expected to be effective against emerging viral variants with various mutations in the spike protein.
RedHill Biopharma Receives Allowances for U S Patent Applications Covering Opaganib and RHB-107 for COVID-19 yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
(1)
Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients
The 464-patient global Phase 2/3 COVID-19 study is over 75% enrolled, with completion of enrollment expected in the coming weeks
Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication
TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva